Kim Pena del Aguila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kim Pena del Aguila has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Amanda L. Elchynski
Department of Pharmacy Arkansas Children’s Hospital Little Rock Arkansas USA
1 shared publication - Brian Hemendra Ramnaraign
University of Florida Dept of Medicine Gainesville, FL
1 shared publication - David L. DeRemer
Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA
1 shared publication - Dennie V. Jones
University of Florida Health Cancer Center Gainesville Florida USA
1 shared publication Elizabeth Eddy
Department of Pharmacotherapy and Translational Research University of Florida College of Pharmacy Gainesville Florida USA
1 shared publication- Emily J. Cicali
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy University of Florida Gainesville Florida USA
1 shared publication
Latest Publications
- Open Access
- 24 July 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (7) , e13890
Implementation of a pharmacogenetic panel‐based test for pharmacotherapy‐based supportive care in an adult oncology clinic
The University of Florida Health conducted a pragmatic implementation of a pharmacogenetics (PGx) panel‐based test to guide medications used for supportive care prescribed to patients undergoing chemotherapy. The implementation was in the context of a pragmatic clinical trial for patients with non‐hematologic cancers being treated with chemotherapy. Patients were randomized to either the intervention arm or control arm and received PGx testing immediately or at the end of the study, respectively. Patients completed the MD Anderson Symptom Inventory (MDASI) to assess quality of life (QoL). A total of 150 patients received PGx testing and enrolled in the study. Clinical decision support and implementation infrastructure were developed. While the study was originally planned for 500 patients, we were underpowered in our sample of 150 patients to test differences in the patient‐reported MDASI scores. We did observed a high completion rate (92%) of the questionnaires; however, there were few medication changes (n = 6 in the intervention arm) based on PGx test results. Despite this, we learned several lessons through this pragmatic implementation of a PGx panel‐based test in an outpatient oncology setting. Most notably, patients were less willing to undergo PGx testing if the cost of the test exceeded $100. In addition, to enhance PGx implementation success, reoccurring provider education is necessary, clinical decision support needs to appear in a more conducive way to fit in with oncologists' workflow, and PGx test results need to be available earlier in treatment planning.
- 24 July 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (7) , e13890
Open AccessImplementation of a pharmacogenetic panel‐based test for pharmacotherapy‐based supportive care in an adult oncology clinic
The University of Florida Health conducted a pragmatic implementation of a pharmacogenetics (PGx) panel‐based test to guide medications used for supportive care prescribed to patients undergoing chemotherapy. The implementation was in the context of a pragmatic clinical trial for patients with non‐hematologic cancers being treated with chemotherapy. Patients were randomized to either the intervention arm or control arm and received PGx testing immediately or at the end of the study, respectively. Patients completed the MD Anderson Symptom Inventory (MDASI) to assess quality of life (QoL). A total of 150 patients received PGx testing and enrolled in the study. Clinical decision support and implementation infrastructure were developed. While the study was originally planned for 500 patients, we were underpowered in our sample of 150 patients to test differences in the patient‐reported MDASI scores. We did observed a high completion rate (92%) of the questionnaires; however, there were few medication changes (n = 6 in the intervention arm) based on PGx test results. Despite this, we learned several lessons through this pragmatic implementation of a PGx panel‐based test in an outpatient oncology setting. Most notably, patients were less willing to undergo PGx testing if the cost of the test exceeded $100. In addition, to enhance PGx implementation success, reoccurring provider education is necessary, clinical decision support needs to appear in a more conducive way to fit in with oncologists' workflow, and PGx test results need to be available earlier in treatment planning.